<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449110</url>
  </required_header>
  <id_info>
    <org_study_id>CEBAS-CSIC-1</org_study_id>
    <nct_id>NCT01449110</nct_id>
  </id_info>
  <brief_title>Resveratrol-enriched Grape Extract (Stilvid) in Primary and Secondary Prevention of Cardiovascular Disease</brief_title>
  <acronym>FUNGRAPE</acronym>
  <official_title>A Randomized, 12 Months Follow-up, Dose-response, Placebo-Controlled, Double-Blind, 6-Arms Parallel Trial to Evaluate the Safety and Efficacy of a Resveratrol-enriched Grape Extract (Stilvid) in Primary and Secondary Patients of Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Council, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital General Universitario Morales Meseguer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Research Council, Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resveratrol can exhibit benefits against cardiovascular diseases (CVDs) although the
      cardioprotective role of resveratrol as part of the human diet is not yet clear.

      The aim of this trial is to evaluate the safety and efficacy of a resveratrol-enriched grape
      extract (Stilvid) in 150 patients from both primary and secondary cardiovascular prevention.

      All the patients are gold-standard medicated (statins and others). A number of cardiovascular
      risk and safety markers will be evaluated after consuming 1 cap/day for 6 months and 2
      caps/day for 6 additional months (total 12 months).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apolipoprotein-B</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>oxidized LDL particles</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasminogen activator inhibitor type 1 (PAI-1)</measure>
    <time_frame>6 months and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>6 months and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>C Reactive Protein</measure>
    <time_frame>6 months 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-10</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-18</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sICAM-1</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sVCAM-1</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GGT</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urate</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDH</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSH</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroxine</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALP</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPK</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinin</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean corpuscular volume</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leucocytes</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophils</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocytes</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophils</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean platelet volume</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedimentation rate volume</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression profile in peripheral blood mononuclear cells (PBMNCs)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Transcriptomic study. Evaluation of the gene expression profile in PBMNCs in a diabetic sub-group from Secondary prevention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total homocystein levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Total homocystein levels in plasma evaluated with UPLC-MS-QqQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of atheroma plaque and carotid intim thickness</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Placebo in PP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm in primary cardiovascular prevention (PP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in SP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm in secondary cardiovascular prevention (SP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grape extract in PP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Grape extract obtained without resveratrol in primary cardiovascular prevention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Grape extract in SP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Grape extract without resveratrol in secondary cardiovascular prevention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resveratrol-enriched grape extract in PP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resveratrol-enriched grape extract (Stilvid) in primary cardiovascular prevention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resveratrol-enriched grape extract in SP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resveratrol-enriched grape extract (Stilvid) in secondary cardiovascular prevention</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo in primary cardiovascular prevention (PP)</intervention_name>
    <description>12 months follow-up:
capsule/day of placebo (350 mg maltodextrin) for 6 months
capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months</description>
    <arm_group_label>Placebo in PP</arm_group_label>
    <other_name>Group A-PP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo in secondary prevention</intervention_name>
    <description>12 months follow-up:
capsule/day (350 mg maltodextrin) for 6 months
capsules/day (350 mg + 350 mg maltodextrin) for 6 months</description>
    <arm_group_label>Placebo in SP</arm_group_label>
    <other_name>Group A-SP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Grape extract in primary prevention (PP)</intervention_name>
    <description>12 months follow-up:
capsule/day (350 mg grape extract) for 6 months
capsules/day (350 mg + 350 mg grape extract) for 6 months</description>
    <arm_group_label>Grape extract in PP</arm_group_label>
    <other_name>Group B-PP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Grape extract in SP</intervention_name>
    <description>12 months follow-up:
capsule/day (350 mg grape extract) for 6 months
capsules/day (350 mg + 350 mg grape extract) for 6 months</description>
    <arm_group_label>Grape extract in SP</arm_group_label>
    <other_name>Group B-SP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol-enriched grape extract in PP</intervention_name>
    <description>Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.
12 months follow-up:
capsule/day (350 mg resveratrol-enriched grape extract) for 6 months
capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months</description>
    <arm_group_label>Resveratrol-enriched grape extract in PP</arm_group_label>
    <other_name>Group C-PP</other_name>
    <other_name>Stilvid is the key ingredient of Revidox (Actafarma, Spain)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol-enriched grape extract in SP</intervention_name>
    <description>Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.
12 months follow-up:
capsule/day (350 mg resveratrol-enriched grape extract) for 6 months
capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months</description>
    <arm_group_label>Resveratrol-enriched grape extract in SP</arm_group_label>
    <other_name>Group C-SP</other_name>
    <other_name>Stilvid is the key ingredient of Revidox (Actafarma, Spain)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        FOR PRIMARY PREVENTION:

          -  Lack of known cardiovascular disease (coronary acute syndrome, stable ischemic
             cardiopathy, peripheric arteriopathy and cerebrovascular diseases).

          -  Age between 18 and 80 years.

          -  The above criteria and diabetes mellitus or at least two of the following risk
             factors:

               1. Active smoking (10 cigarettes or more per day).

               2. Arterial hypertension (&gt;= 140/90 mmHg).

               3. Hypercholesterolemia (LDL-cholesterol &gt;130 mg/dL and/or HDL-cholesterol &lt; 45
                  mg/dL in women and 50 mg/dL in men).

               4. Obesity (BMI &gt; 30 kg/m2)

        FOR SECONDARY PREVENTION:

          -  Stable patients who coronary syndrome, cerebrovascular accident or peripheric
             arteriopathy event occurred at least 6 months or more before the recruitment in the
             study. In addition:

               1. Age between 18 and 80 years.

               2. Ejection fraction of left ventricle &gt;=45%.

               3. Functional status I or II according to the New York Heart Association.

               4. Clinic stability in the recruitment (no symptoms of thoracic pain during the last
                  month).

               5. Lack of residual lesions without vascularization in those patients with
                  catheterism.

                  Exclusion Criteria:

                  FOR PRIMARY AND SECONDARY PREVENTION:

          -  Patients who do not satisfy inclusion criteria and:

               1. Known allergy to grapes

               2. Pregnancy or lactation

               3. Intake of nutraceuticals
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Carlos Espín, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Council (CEBAS-CSIC, Murcia, Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <last_update_submitted>November 15, 2011</last_update_submitted>
  <last_update_submitted_qc>November 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Council, Spain</investigator_affiliation>
    <investigator_full_name>Juan Carlos Espín de Gea</investigator_full_name>
    <investigator_title>Research Professor</investigator_title>
  </responsible_party>
  <keyword>Primary prevention</keyword>
  <keyword>Secondary prevention</keyword>
  <keyword>Resveratrol</keyword>
  <keyword>Grape</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Nutraceutical</keyword>
  <keyword>Food complement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

